Reverse the Resistance to PARP Inhibitors

被引：68

作者：

Kim, Yevgeniy ^{[1
]}

Kim, Aleksei ^{[1
]}

Sharip, Ainur ^{[1
]}

Sharip, Aigul ^{[1
]}

Jiang, Juhong ^{[2
]}

Yang, Qing ^{[1
]}

Xie, Yingqiu ^{[1
]}

机构：

[1] Nazarbayev Univ, Sch Sci & Technol, Dept Biol, 53 Kabanbay Batyr Ave, Astana 010000, Kazakhstan

[2] Guangzhou Med Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Guangdong, Peoples R China

来源：

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2017年 / 13卷 / 02期

基金：

中国国家自然科学基金;

关键词：

PARP; PARP inhibitor; drug resistance; DNA repair; STRAND-BREAK REPAIR; SHOCK-PROTEIN; 90; HOMOLOGOUS RECOMBINATION; DNA-REPAIR; SECONDARY MUTATIONS; SYNTHETIC LETHALITY; MILD HYPERTHERMIA; TUMOR SUPPRESSION; CANCER-CELLS; BRCA1;

D O I：

10.7150/ijbs.17240

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

One of the DNA repair machineries is activated by Poly ( ADP- ribose) Polymerase ( PARP) enzyme. Particularly, this enzyme is involved in repair of damages to single- strand DNA, thus decreasing the chances of generating double- strand breaks in the genome. Therefore, the concept to block PARP enzymes by PARP inhibitor ( PARPi) was appreciated in cancer treatment. PARPi has been designed and tested for many years and became a potential supplement for the conventional chemotherapy. However, increasing evidence indicates the appearance of the resistance to this treatment. Specifically, cancer cells may acquire new mutations or events that overcome the positive effect of these drugs. This paper describes several molecular mechanisms of PARPi resistance which were reported most recently, and summarizes some strategies to reverse this type of drug resistance.

引用

页码：198 / 208

页数：11

共 122 条

[1] PARP inhibitors [J].

Anwar, Maheen ;

Aslam, Hafiz Muhammad ;

Anwar, Shahzad .

HEREDITARY CANCER IN CLINICAL PRACTICE, 2015, 13

[2] Genetic Interactions in Cancer Progression and Treatment [J].

Ashworth, Alan ;

Lord, Christopher J. ;

Reis-Filho, Jorge S. .

CELL, 2011, 145 (01) :30-38

[3] Drug Resistance Caused by Reversion Mutation [J].

Ashworth, Alan .

CANCER RESEARCH, 2008, 68 (24) :10021-10023

[4] Heat Shock Protein 90 Is Critical for Regulation of Phenotype and Functional Activity of Human T Lymphocytes and NK Cells [J].

Bae, Jooeun ;

Munshi, Aditya ;

Li, Cheng ;

Samur, Mehmet ;

Prabhala, Rao ;

Mitsiades, Constantine ;

Anderson, Kenneth C. ;

Munshi, Nikhil C. .

JOURNAL OF IMMUNOLOGY, 2013, 190 (03) :1360-1371

[5] Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line [J].

Baldan, Federica ;

Mio, Catia ;

Allegri, Lorenzo ;

Puppin, Cinzia ;

Russo, Diego ;

Filetti, Sebastiano ;

Damante, Giuseppe .

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015

[6] Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor [J].

Barber, Louise J. ;

Sandhu, Shahneen ;

Chen, Lina ;

Campbell, James ;

Kozarewa, Iwanka ;

Fenwick, Kerry ;

Assiotis, Ioannis ;

Rodrigues, Daniel Nava ;

Reis Filho, Jorge S. ;

Moreno, Victor ;

Mateo, Joaquin ;

Molife, L. Rhoda ;

De Bono, Johann ;

Kaye, Stan ;

Lord, Christopher J. ;

Ashworth, Alan .

JOURNAL OF PATHOLOGY, 2013, 229 (03) :422-429

[7] Inhibition of homologous recombination by hyperthermia shunts early double strand break repair to non-homologous end-joining [J].

Bergs, Judith W. J. ;

Krawczyk, Przemek M. ;

Borovski, Tijana ;

ten Cate, Rosemarie ;

Rodermond, Hans M. ;

Stap, Jan ;

Medema, Jan Paul ;

Haveman, Jaap ;

Essers, Jeroen ;

van Bree, Chris ;

Stalpers, Lukas J. A. ;

Kanaar, Roland ;

Aten, Jacob A. ;

Franken, Nicolaas A. P. .

DNA REPAIR, 2013, 12 (01) :38-45

[8] Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? [J].

Borst, Piet .

OPEN BIOLOGY, 2012, 2

[9] Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors? [J].

Bouwman, Peter ;

Jonkers, Jos .

CLINICAL CANCER RESEARCH, 2014, 20 (03) :540-547

[10] 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers [J].

Bouwman, Peter ;

Aly, Amal ;

Escandell, Jose M. ;

Pieterse, Mark ;

Bartkova, Jirina ;

van der Gulden, Hanneke ;

Hiddingh, Sanne ;

Thanasoula, Maria ;

Kulkarni, Atul ;

Yang, Qifeng ;

Haffty, Bruce G. ;

Tommiska, Johanna ;

Blomqvist, Carl ;

Drapkin, Ronny ;

Adams, David J. ;

Nevanlinna, Heli ;

Bartek, Jiri ;

Tarsounas, Madalena ;

Ganesan, Shridar ;

Jonkers, Jos .

NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2010, 17 (06) :688-U56

← 1 2 3 4 5 6 7 8 9 10 →